Teva Pharmaceutical Industries Ltd (TEVA) Receives $22.91 Average PT from Brokerages
Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) have received an average rating of “Hold” from the twenty-three analysts that are covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a sell recommendation, thirteen have assigned a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $22.29.
Several equities research analysts have weighed in on TEVA shares. Credit Suisse Group cut their target price on shares of Teva Pharmaceutical Industries from $26.00 to $20.00 and set a “neutral” rating on the stock in a report on Thursday. Raymond James upgraded shares of Teva Pharmaceutical Industries from a “market perform” rating to an “outperform” rating and set a $22.00 target price on the stock in a report on Thursday. Maxim Group reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Thursday. Wells Fargo & Co reiterated a “hold” rating and issued a $20.00 target price (down from $24.00) on shares of Teva Pharmaceutical Industries in a report on Thursday. They noted that the move was a valuation call. Finally, Oppenheimer reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Monday, February 11th.
In related news, VP Hafrun Fridriksdottir sold 1,643 shares of the firm’s stock in a transaction on Wednesday, January 2nd. The shares were sold at an average price of $15.70, for a total transaction of $25,795.10. Following the sale, the vice president now directly owns 13,469 shares in the company, valued at $211,463.30. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Notaristefani Carlo De sold 5,041 shares of the firm’s stock in a transaction on Wednesday, February 13th. The stock was sold at an average price of $17.88, for a total transaction of $90,133.08. Following the sale, the vice president now owns 17,162 shares in the company, valued at $306,856.56. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 7,617 shares of company stock worth $136,230. 0.43% of the stock is currently owned by company insiders.
Shares of TEVA stock opened at $17.98 on Wednesday. Teva Pharmaceutical Industries has a 52-week low of $14.59 and a 52-week high of $25.96. The company has a market capitalization of $18.28 billion, a price-to-earnings ratio of 6.42, a price-to-earnings-growth ratio of 7.20 and a beta of 1.46. The company has a current ratio of 0.94, a quick ratio of 0.61 and a debt-to-equity ratio of 1.75.
Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, February 13th. The company reported $0.53 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.53. Teva Pharmaceutical Industries had a negative net margin of 11.40% and a positive return on equity of 18.57%. The firm had revenue of $4.56 billion for the quarter, compared to analysts’ expectations of $4.52 billion. During the same period last year, the firm earned $0.93 earnings per share. The business’s revenue for the quarter was down 15.5% on a year-over-year basis. As a group, equities analysts anticipate that Teva Pharmaceutical Industries will post 2.65 earnings per share for the current year.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Featured Article: Liquidity
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.